Renal Cell Carcinoma
Conditions
Brief summary
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.
Interventions
DRUGLenvatinib
Lenvatinib will be provided by Merck.
DRUGPembrolizumab
Merck will provide pembrolizumab
PROCEDUREResearch blood collection
-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
Sponsors
Merck Sharp & Dohme LLC
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced or metastatic histologically confirmed nccRCC (2, 7). Must have one of the following subtypes of nccRCC: * papillary RCC * chromophobe RCC * TFE-3/B translocation RCC * SDHB-loss RCC * TSC1-loss RCC * sarcomatoid RCC without clear cell component * unclassified RCC * Has not received any prior lines of systemic therapy except adjuvant or neoadjuvant treatments. * Radiologically measurable disease meeting the following criteria: * At least 1 lesion of ≥ 10 mm in the longest diameter for a non-lymph node or ≥ 15 mm in the short axis diameter for a lymph node which is serially measurable according to iRECIST (Section 12) using computerized tomography (CT) or magnetic resonance imaging (MRI). * Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of subsequent progressive disease (substantial size increase of ≥20%) to be deemed a target lesion. Patients who received EBRT must be at least 2 weeks out from last RT treatment. * At least 18 years of age. * Karnofsky performance status ≥ 70% * Blood pressure (BP) ≤ 150/90 mmHg at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1. * Adequate renal function defined as creatinine \<1.5 x ULN or calculated creatinine clearance ≥40 mL/min per the Cockcroft and Gault formula with creatinine levels \>1.5 x ULN. * Adequate bone marrow function: * Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 x 103/L) * Platelets ≥100,000/mm3 (≥100 x 109/L) * Hemoglobin ≥9.0 g/dL * Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤1.5 * Adequate liver function as evidenced by: * bilirubin ≤1.5 times the upper limit of normal (ULN) * alkaline phosphatase (ALP) ≤3×ULN (in the case of liver metastases ≤5×ULN) * alanine aminotransferase (ALT) ≤3×ULN (in the case of liver metastases ≤5×ULN) * aspartate aminotransferase (AST) ≤3×ULN (in the case of liver metastases ≤5×ULN). In case ALP is \>3×ULN (in the absence of liver metastases) or \>5×ULN (in the presence of liver metastases) AND the subject also is known to have bone metastases, the liver specific ALP isoenzyme must be separated from the total and used to assess the liver function instead of the total ALP. * Subjects with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection) and if they have remained clinically stable, asymptomatic, and off steroids for at least 2 months before starting study treatment. * All females of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin \[β-hCG\]) at the screening visit. Females of childbearing potential\* must agree to use a highly effective method of contraception for the entire study period and for 120 days after study discontinuation * Male subjects who are partners of women of childbearing potential must follow one of the methods of contraception described in Section 6.5 beginning at least 1 menstrual cycle prior to starting study drugs, throughout the entire study period, and for 120 days after the last dose of study drug, unless the male subjects are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile. * Archival tumor tissue from within 3 months (preferred) or up to 6 months (acceptable) must be available prior to the first dose of study drug for biomarker analysis. If no biopsy has been performed in the prior 6 months, a standard of care biopsy is requested if safe and feasible. In the case tissue cannot be provided, patients can be enrolled upon consultation and agreement by the trial PI. Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 14 days from when the slides are cut. -Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion criteria
* Predominant clear cell renal cell carcinoma (RCC) * Uncontrolled or untreated brain metastasis * Major surgery performed within 4 weeks prior to the first dose of study drugs or scheduled for major surgery during the study. Subjects must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy. * Subjects having \>1+ proteinuria on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥1 g/24-hour will be ineligible. * Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib. * New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months. * Prolongation of QTc interval to \>480 msec. * Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug. * Active infection (any infection requiring systemic treatment). * Subject is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C * Serious nonhealing wound, ulcer, or bone fracture. * Known intolerance to either of the study drugs (or any of the excipients). * History of organ allograft (subject has had an allogenic tissue/solid organ transplant) or allogeneic stem cell transplant (subject has received blood-forming stem cells from a donor). * Biologic response modifiers (e.g., granulocyte colony-stimulating factor) within 4 weeks before study entry. Chronic erythropoietin therapy is permitted provided that no dose adjustments were made within 2 months before first dose of study treatment. * Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial. * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. If the required urine pregnancy test is positive (or cannot be confirmed as negative) within 72 hours prior to start of treatment, a serum pregnancy test will be required. * Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 36 months. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of up to 10 mg/day of prednisone or equivalent is approved and does not exclude the patient from the trial. * Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, \> 10 mg of prednisone per day, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. The use of up to 10 mg/day of prednisone or equivalent is approved and does not exclude the patient from the trial. * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required maintenance steroids (\>10 mg of prednisone) or current pneumonitis/interstitial lung disease. * Has received a live-virus vaccination or live-attenuated vaccine within 30 days of planned treatment start. Administration of killed vaccines is allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Through completion of treatment (median length 287 days, full range 92-728 days) | * ORR is defined as the proportion of subjects who have a best overall response of complete response (CR) or partial response (PR) * CR: Disappearance of target and non-target lesions and normalization of tumor markers. * PR: At least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non target lesions must be non-progressive disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | From start of treatment through 120 days after last day of study treatment (median length of follow-up 397 days, full range 92-848 days) | -Will be graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
| Cumulative Probability of Progression-free Survival (PFS) | At 3 months | * PFS is defined as the time from date of first dose of study drug to date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). * Cumulative probability is on a scale of 0-1. |
| Median Progression-free Survival (PFS) | Through completion of follow-up (median length 602 days, full range 92-1244 days) | * PFS is defined as the time from date of first dose of study drug to date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). |
| Median Overall Survival (OS) | Through completion of follow-up (median length 602 days, full range 92-1244 days) | -OS is defined as the time from the date of first dose of study drug until date of death from any cause. |
| Cumulative Probability of Overall Survival (OS) | At 6 months | * OS is defined as the time from the date of first dose of study drug until date of death from any cause. * Cumulative probability is on a scale of 0-1. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lenvatinib + Pembrolizumab * Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.
* Subjects may be treated with pembrolizumab for a maximum of 35 cycles or approximately 2 years, but treatment with lenvatinib can continue beyond 2 years if the subject does not meet other treatment discontinuation criteria. | 11 |
| Total | 11 |
Baseline characteristics
| Characteristic | Lenvatinib + Pembrolizumab |
|---|---|
| Age, Continuous | 57 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 9 Participants |
| Region of Enrollment United States | 11 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 8 / 11 |
| other Total, other adverse events | 11 / 11 |
| serious Total, serious adverse events | 6 / 11 |
Outcome results
Primary
Overall Response Rate (ORR)
* ORR is defined as the proportion of subjects who have a best overall response of complete response (CR) or partial response (PR) * CR: Disappearance of target and non-target lesions and normalization of tumor markers. * PR: At least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non target lesions must be non-progressive disease.
Time frame: Through completion of treatment (median length 287 days, full range 92-728 days)
Population: One patient was not evaluable as they did not have a disease assessment outside of the baseline disease assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Overall Response Rate (ORR) | 4 Participants |
Secondary
Cumulative Probability of Overall Survival (OS)
* OS is defined as the time from the date of first dose of study drug until date of death from any cause. * Cumulative probability is on a scale of 0-1.
Time frame: At 18 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Overall Survival (OS) | 0.6364 probability |
Secondary
Cumulative Probability of Overall Survival (OS)
* OS is defined as the time from the date of first dose of study drug until date of death from any cause. * Cumulative probability is on a scale of 0-1.
Time frame: At 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Overall Survival (OS) | 0.9091 probability |
Secondary
Cumulative Probability of Overall Survival (OS)
* OS is defined as the time from the date of first dose of study drug until date of death from any cause. * Cumulative probability is on a scale of 0-1.
Time frame: At 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Overall Survival (OS) | 0.8182 probability |
Secondary
Cumulative Probability of Progression-free Survival (PFS)
* PFS is defined as the time from date of first dose of study drug t date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). * Cumulative probability is on a scale of 0-1.
Time frame: At 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Progression-free Survival (PFS) | 0.9091 probability |
Secondary
Cumulative Probability of Progression-free Survival (PFS)
* PFS is defined as the time from date of first dose of study drug t date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). * Cumulative probability is on a scale of 0-1.
Time frame: At 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Progression-free Survival (PFS) | 0.7273 probability |
Secondary
Cumulative Probability of Progression-free Survival (PFS)
* PFS is defined as the time from date of first dose of study drug to date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). * Cumulative probability is on a scale of 0-1.
Time frame: At 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Cumulative Probability of Progression-free Survival (PFS) | 1.0000 probability |
Secondary
Median Overall Survival (OS)
-OS is defined as the time from the date of first dose of study drug until date of death from any cause.
Time frame: Through completion of follow-up (median length 602 days, full range 92-1244 days)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Median Overall Survival (OS) | 19.78 months |
Secondary
Median Progression-free Survival (PFS)
* PFS is defined as the time from date of first dose of study drug to date of first documentation of disease progression or death, whichever occurs first. * Progressive disease: At least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥5 mm. Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas).
Time frame: Through completion of follow-up (median length 602 days, full range 92-1244 days)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenvatinib + Pembrolizumab | Median Progression-free Survival (PFS) | 19.78 months |
Secondary
Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant
-Will be graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Time frame: From start of treatment through 120 days after last day of study treatment (median length of follow-up 397 days, full range 92-848 days)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Adrenal insufficiency | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Abdominal pain | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Alanine aminotransferase increased | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Alopecia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Anemia | 3 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Anorexia | 5 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Aspartate aminotransferase increased | 3 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Cholesterol high | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Cognitive disturbance | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Constipation | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Creatinine increased | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Depression | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Diarrhea | 6 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Dizziness | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Dry skin | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Dysgeusia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Dysphagia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Enterocolitis infectious | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Eosinophilia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Erythematous rash | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Fatigue | 6 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Fecal incontinence | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Generalized edema | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Headache | 3 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Hemorrhoids | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Hernia surgery | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Hoarseness | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Hypertension | 6 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Hyperthyroidism | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Ileus | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Incisional hernia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Insomnia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Intra-abdominal hemorrhage | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Itchy scalp | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Jejunal fistula | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Mucositis oral | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Myalgia | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Nail discoloration | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Nausea | 6 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Neutrophil count decreased | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Non-cardiac chest pain | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Pain - bottoms of feet | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Palmar-plantar erythrodysesthesia syndrome | 5 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Papulopustular rash | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Peripheral sensory neuropathy | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Platelet count decreased | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Proteinuria | 4 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Pruritus | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Pruritic Rash | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Rash | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Rash acneiform | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Rash maculo-papular | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Restless Leg Syndrome | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Scalp sores | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Sensitive Hands | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Sensitive skin/sores on face | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Skin Soreness | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Sore throat | 2 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Stomach pain | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Thyroid stimulating hormone increased | 8 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Vision decreased | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Vitiligo | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Voice alteration | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Vomiting | 3 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Warm hands and feet | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | White blood cell decreased | 1 Participants |
| Lenvatinib + Pembrolizumab | Safety and Tolerability of Regimen as Measured by Related Adverse Events Experienced by Participant | Weight loss | 2 Participants |